In a late-breaking abstract presentation at the ERS Congress 2025, aTyr Pharma reported positive findings from the Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis. Results showed improvements in the Fatigue Assessment Scale Total Score and King’s Sarcoidosis Questionnaire-General Health score in the 5.0 mg/kg efzofitimod treatment group compared to placebo. While the study did not meet its primary endpoint, efzofitimod demonstrated potential benefits in multiple disease-related health outcomes, including cough, shortness of breath, fatigue, and general health. Further analyses revealed a trend towards steroid-free status in some patients treated with efzofitimod.

Pulmonary sarcoidosis affects approximately 200,000 Americans, with limited treatment options and potential for permanent lung damage. Efzofitimod, a first-in-class biologic immunomodulator, showed promise in improving quality of life for patients with interstitial lung disease. Although the study did not achieve its primary endpoint, efzofitimod exhibited positive clinical benefits across various efficacy parameters. The statistical analysis plan for the study was based on a hierarchical assessment, with all subsequent testing reported as nominal findings.

In conclusion, aTyr Pharma’s efzofitimod presents potential therapeutic benefits for pulmonary sarcoidosis patients by addressing critical symptoms and improving quality of life measures. Despite missing the primary endpoint, the drug showed significant improvements in various disease-related health outcomes. The company remains optimistic about efzofitimod’s ability to enhance patient outcomes and reduce reliance on chronic steroids in the treatment of pulmonary sarcoidosis.

Read more at GlobeNewswire: aTyr Pharma Presents Additional Findings from Phase 3